Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash & Equivalents (2016 - 2026)

Niagen Bioscience has reported Cash & Equivalents over the past 11 years, most recently at $64.8 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 45.07% to $64.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.8 million through Dec 2025, up 45.07% year-over-year, with the annual reading at $64.8 million for FY2025, 45.07% up from the prior year.
  • Cash & Equivalents was $64.8 million for Q4 2025 at Niagen Bioscience, up from $64.3 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $64.8 million in Q4 2025 and troughed at $13.3 million in Q3 2022.
  • The 5-year median for Cash & Equivalents is $28.1 million (2021), against an average of $34.9 million.
  • Year-over-year, Cash & Equivalents skyrocketed 228.48% in 2021 and then tumbled 59.94% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $28.2 million in 2021, then fell by 27.56% to $20.4 million in 2022, then surged by 33.68% to $27.3 million in 2023, then soared by 63.44% to $44.7 million in 2024, then soared by 45.07% to $64.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Cash & Equivalents are $64.8 million (Q4 2025), $64.3 million (Q3 2025), and $60.5 million (Q2 2025).